Weikang Bio-technology Group, Inc. ("Weikang") Participated in 66th National Drug Trade Fair

HARBIN, China, Dec. 6, 2011 /PRNewswire-Asia-FirstCall/ -- From December 1-3, 2011, Weikang participated in China's 66th National Drug Trade Fair held in Zhengzhou, the capital of Henan Province. Weikang had two booths staffed by 16 people participating in the fair. During the fair, Weikang reached or extended various agreements with distributors.

Mr. Wang, the Chairman and CEO of Weikang commented: "We are very glad about the effect of participating in this fair, which is the largest drug fair with the longest history in China. Weikang has always participated in this fair in recent years and each time it has been a major channel of promotion for our products." Mr. Wang continued, "We not only secured distribution agreements, but also greatly promoted the image of our products in the marketplace, which we believe will lead to more distribution contracts in the future."

About China's 66th National Drug Trade Fair:

The fair is known as the largest drug trade fair in China. This year it covered a 65,000 square meter area, with 3200 booths and more than 2000 companies participating. The total number of professionals that visited the fair this year reached 100,000.

About Weikang Bio-Technology Group Co., Inc.

Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang Pharmaceutical Co., Ltd.  For more information, please visit http://www.weikangbio.com.

Safe Harbor Statement

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995.  These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

SOURCE Weikang Bio-Technology Group Co., Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED